Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women

Wade KC, Ellenberg JH, Grosser T, Brensinger CM, Kimmel SE, Hennessy S (2011)
Journal of Cardiovascular Pharmacology 57(2): 194-200.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Wade, Kelly C; Ellenberg, Jonas H; Grosser, TiloUniBi ; Brensinger, Colleen M; Kimmel, Stephen E; Hennessy, Sean
Abstract / Bemerkung
Rofecoxib has been proposed to increase the risk of myocardial infarction (MI) through suppression of cyclooxygenase 2-mediated prostacyclin. Estrogen may have protective effects through augmenting cyclooxygenase 2 expression and subsequently increasing prostacyclin. Estrogen may attenuate the association between rofecoxib and MI. We used 1999-2002 Medicaid claims data to measure the MI hazard ratio (HR) attributed to rofecoxib exposure in estrogen-exposed and unexposed 45- to 65-year-old women. We identified 184,169 female rofecoxib users who contributed 309,504 person-years and experienced 1217 first MIs. Estrogen exposure seemed protective [MI-HR 0.72; 95% confidence interval (CI), 0.62-0.84] in this cohort. Rofecoxib was associated with an elevated MI-HR in both estrogen-exposed (2.01; 95% CI, 1.60-2.54) and estrogen-unexposed women (1.69; 95% CI, 1.43-1.99). The rofecoxib-estrogen interaction ratio was not significantly different from 1 (1.19; 95% CI, 0.91-1.57). Although estrogen use was associated with a lower risk of MI, it did not seem to attenuate the association between rofecoxib and MI.
Erscheinungsjahr
2011
Zeitschriftentitel
Journal of Cardiovascular Pharmacology
Band
57
Ausgabe
2
Seite(n)
194-200
ISSN
0160-2446
Page URI
https://pub.uni-bielefeld.de/record/2965327

Zitieren

Wade KC, Ellenberg JH, Grosser T, Brensinger CM, Kimmel SE, Hennessy S. Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women. Journal of Cardiovascular Pharmacology. 2011;57(2):194-200.
Wade, K. C., Ellenberg, J. H., Grosser, T., Brensinger, C. M., Kimmel, S. E., & Hennessy, S. (2011). Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women. Journal of Cardiovascular Pharmacology, 57(2), 194-200. https://doi.org/10.1097/FJC.0b013e31820350d3
Wade, Kelly C, Ellenberg, Jonas H, Grosser, Tilo, Brensinger, Colleen M, Kimmel, Stephen E, and Hennessy, Sean. 2011. “Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women”. Journal of Cardiovascular Pharmacology 57 (2): 194-200.
Wade, K. C., Ellenberg, J. H., Grosser, T., Brensinger, C. M., Kimmel, S. E., and Hennessy, S. (2011). Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women. Journal of Cardiovascular Pharmacology 57, 194-200.
Wade, K.C., et al., 2011. Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women. Journal of Cardiovascular Pharmacology, 57(2), p 194-200.
K.C. Wade, et al., “Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women”, Journal of Cardiovascular Pharmacology, vol. 57, 2011, pp. 194-200.
Wade, K.C., Ellenberg, J.H., Grosser, T., Brensinger, C.M., Kimmel, S.E., Hennessy, S.: Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women. Journal of Cardiovascular Pharmacology. 57, 194-200 (2011).
Wade, Kelly C, Ellenberg, Jonas H, Grosser, Tilo, Brensinger, Colleen M, Kimmel, Stephen E, and Hennessy, Sean. “Exogenous Estrogen Does Not Attenuate the Association Between Rofecoxib and Myocardial Infarction in Perimenopausal Women”. Journal of Cardiovascular Pharmacology 57.2 (2011): 194-200.
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 21052013
PubMed | Europe PMC

Suchen in

Google Scholar